Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Apr 25, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA Phase 3 trials of ...
Apr 24, 2018
-Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30pm ET- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will rel...
Apr 19, 2018
- Lead product for treatment of glabellar lines on track to report SAKURA Phase 3 open-label safety results in second half of 2018 - - Initiating Phase 3 pivotal trial for cervical dystonia in current quarter - - Company to add RT002 clinical programs in adult upper limb s...
Apr 2, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic and Therapeutic; ...
Mar 26, 2018
-Webcast to begin at 12:00pm ET- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will host a live web...
Mar 20, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York, NY. ...
Mar 6, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the company will participate in two upcoming investor conferences. Pres...
Feb 28, 2018
- Announces collaboration and license agreement with Mylan for proposed biosimilar to BOTOX® - -Cash and investments of approximately $283 million as of December 31, 2017- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnolog...
  Feb 28, 2018
Feb 22, 2018
Conference Call Scheduled for Wednesday, February 28, 2018 at 4:30pm ET NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announce...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools